Physician profile
Ryan L Grayburn
NPI 1841415098
$4,489.06
in general payments reported to CMS, 2019-2025
19 companies · $811 in 2025
The $811 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $175 · 2021: $401 · 2022: $271 · 2023: $554 · 2024: $1,825 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968 · Travel and Lodging: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.34 |
| Travel and Lodging | $1,221.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| One Lambda, INC. | $1,613.92 | 2024 | |
| Abbott Laboratories | $1,439.61 | 2019-2025 | Cardiomems, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $292.11 | 2023-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $191.79 | 2019-2024 | |
| Medtronic Vascular, INC. | $179.39 | 2019 | |
| Shockwave Medical, INC | $176.81 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $134.07 | 2019-2025 | Wainua |
| Pfizer INC. | $129.01 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.73 | 2019-2023 | Lifevest |
| Boston Scientific Corporation | $59.00 | 2019 | |
| Scpharmaceuticals INC. | $36.06 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.32 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.52 | 2019 | |
| Merck Sharp & Dohme LLC | $16.28 | 2024 | Verquvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14.84 | 2024 | Camzyos |
| Alnylam Pharmaceuticals INC. | $13.70 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.38 | 2024 | |
| Amgen INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Grayburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.